There is a growing concern regarding the recent emergence of the yeast-like fungus, Candida auris, in mainstream news and communications. Since it’s identification in 2009 as a serious health concern, cases of C. auris infection have been reported in over 30 countries, including the United States. The prevalence of C. auris infections in healthcare facilities has increased due to misidentification, its resistance to traditional antifungal treatments, and improper environmental control practices.
C. auris can live on environmental surfaces for a month or longer. Preliminary tests suggest that quaternary ammonium compounds, (commonly used for healthcare disinfection), may not be sufficiently effective against C. auris. In the interim, the CDC recommends that healthcare facilities use an EPA registered disinfectant with efficacy against Clostridium difficile (C. diff) spores to perform daily, thorough cleaning of patient rooms associated with C. auris infection.
Spartan’s product, Diffense, meets the CDC’s recommendation for environmental disinfection. While Diffense is effective against C. difficile, we must emphasize to our customers and distributors that proper use of our products with good procedures will ensure effectiveness. Strict attention to hand hygiene, as well as proper cleaning and disinfection methods, are critical elements in controlling and eliminating the spread of C. auris.
For additional resources, please reference the CDC and EPA links listed below for more detailed information regarding CDC recommendations for C.diff products and on C. auris:
List K: EPA's Registered Antimicrobial Products Effective against Clostridium difficile Spores: